ARMATA PHARMACEUTICALS, INC.
4503 Glencoe Avenue
Marina del Rey, California 90292-3552
April 5, 2022
VIA EDGAR SUBMISSION
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
| Re: | Armata Pharmaceuticals, Inc. (the “Company”) Registration Statement on Form S-3 (File No. 333-263936) (the “Registration Statement”) |
Dear Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended (the “Securities Act”), the Company hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on Wednesday, April 6, 2022, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.
If you have any questions regarding this request, please contact our outside counsel, Faith Charles of Thompson Hine LLP, at (212) 908-3905 or Naveen Pogula of Thompson Hine LLP, at (404) 541-2913. Please also call either Faith Charles or Naveen Pogula as soon as the Company’s Registration Statement on Form S-3 has been declared effective. Thank you for your attention to this matter.
| Sincerely, | ||
| ARMATA PHARMACEUTICALS, INC. | ||
| By: | /s/ Brian Varnum | |
| Name: Brian Varnum | ||
| Title: Chief Executive Officer | ||
| cc: | Brian Varnum, Armata Pharmaceuticals, Inc. |
Faith Charles, Thompson Hine LLP
Naveen Pogula, Thompson Hine LLP
